About
Richard L. Love has 40 years of industry experience, with more than 27 years of leadership roles in the biosciences industry. He started two biopharmaceutical companies and served as CEO for both: Triton Biosciences, Inc., from 1983 to 1991, and ILEX Oncology, Inc., 1994 to 2001. In addition Love has served in executive positions at not-for-profit organizations, including the Cancer Therapy and Research Center, The San Antonio Technology Accelorator Initiative and the Translational Genomics Research Institute (TGen). At Triton and ILEX, Love led teams that were responsible for the clinical development of four important therapeutic products that are currently used in the practice of medicine: Betaseron® for patients with multiple sclerosis; Fludara® and CAMPATH® both for patients with chronic lymphocytic leukemia; and Clolar® for acute leukemias. In 2004 ILEX was acquired by Genzyme Corporation for approximately $1 billion. Currently Love is a managing partner in Translational A
Position in the VCSift Database
- • 145 investors hold the Board of Directors role in VCSift. Richard L. Love is one of them.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
Contact Information
Find more investors like Richard
Search Investors